Biologics in Plaque Psoriasis - Streamlined Drug Class Review
22 September 2023
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] The only other patent filed for infliximab expired March 18, 2012.27 Objectives The objective of this report is to identify and summarize: • The best available evidence regarding the efficacy of new-generation biologics (i.e., class of anti-IL17 and anti-IL23) compared to old-generation biologics (i.e., class of anti-TNF alpha and anti-IL12/23) for the treatment of patients with moderate to severe. [...] The names and backgrounds of the two specialist members will be shared at the conclusion of the review to discourage attempts to directly lobby the specialists. [...] The authors used the total number of studies and participants as a denominator to calculate the proportion of trials and participants used for the quantitative synthesis of each outcome. [...] Assessment of the certainty of the evidence The authors assessed the confidence of the evidence estimates using the Confidence in Network Meta-Analysis (CINeMA) approach, which is based on the contributions of the direct comparisons to the estimation in the network meta-analysis.35 It is based on six domains: within-study bias (the impact of risk of bias in the included studies), across-studies bi.